This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study to Evaluate the Safety and Tolerability of...
Clinical trial

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Read time: 2 mins
Last updated:29th Apr 2019
Identifier: NCT03781167

The purpose of this study is to assess the safety and tolerability of ABBV-951 in subjects with Parkinson's disease (PD).


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 130 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
Actual Study Start Date: April 29, 2019
Estimated Primary Completion Date: April 23, 2021
Estimated Study Completion Date: June 26, 2021

Arm:
- Experimental:
ABBV-951

Category Value
Date last updated at source 2019-09-23
Study type(s) Interventional
Expected enrolment 130
Study start date 2019-04-29
Estimated primary completion date 2021-04-23

View full details